Abstract
BackgroundThe advent of immune checkpoint inhibition (ICI) therapy markedly improved the outcome for melanoma. However, response remains heterogeneous, with about half of the patients being refractory or developing relapse. Although...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
